MilliporeSigma Webinars

41. Developing A Scalable Upstream Bioreactor Process For Lentiviral Vector Production In Suspension 3/8/2021

    Gene therapies hold the promise to change lives. As your path to patients accelerates, how can you assure the robust process design, intensification and scalability that meets your evolving manufacturing needs? And what benefits can a templated process bring to your commercial success? Learn the answers to these questions and more in this webinar.

42. Biosafety In Gene Therapy: Applying The Latest Regulatory Guidance For RCL Testing 2/23/2021

    The use of lentivirus vectors to produce groundbreaking gene therapies is on the rise. Ensuring the biosafety and quality of these vectors is achieved through a multi-tiered testing approach. For lentivirus-based therapies, generation of replication competent particles is a potential risk. While improvements in design and manufacturing have decreased the probability of producing replication competent viruses, regulatory agencies provide guidelines to test for their presence at multiple stages in production.

43. Addressing The Challenge Of Scalability In Viral Vectors 10/18/2020

    Early viral vector process development for cell and gene therapies is critical to assure a production strategy that supports commercial needs. In this webinar, you will learn the importance of planning for scalability and manufacturability from the earliest stages of process development and how a scalable templated process can reduce time needed to move from product development to commercialization. 

44. Navigating The Road To Gene Therapy Commercialization 8/27/2020

    With increases in development and investments in the gene therapy field, companies will increasingly be looking at manufacturing and commercialization of their therapies. Road to commercialization goes through a series of process validation phases. In this webinar, we take a closer look at the road to commercialization and focus on addressing primary questions.

45. Downstream Process Intensification For Virus Purification 8/21/2020

    With the rise of gene therapy as a promising treatment modality, the industry is facing increasing pressure to decrease overall manufacturing costs, shorten product development timelines and increase production. This webinar focuses on intensified downstream process using high-productivity, single-use chromatography membrane adsorbers.

46. Process Development for Cell Therapy and Viral Gene Therapy 10/29/2019

    In this webinar, we discuss our strategies for developing lentivirus and adeno associated virus (AAV) and the impact these early decisions can have on commercial readiness.

47. Process Impurities: Don't Let PEI Or HCP Derail Your Biotherapy

    Learn product characterization strategies to de-risk manufacturing and detect and characterize host cell proteins and polyethylenimine in mAb and cell and gene therapies.

48. Smart Bioprocess Data Utilization For Advanced Analytics And Monitoring With Data Analytics Tools Purpose-Built For Bioprocessing

    We share our experience working with organizations as they adopt solutions for automated data acquisition, aggregation, visualizations, and statistical analysis.